A Phase 1-2 Neoadjuvant Dose Finding, Safety, and Immunologic Efficacy Trial of Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer and Tumor-Specific Intranodal Autologous Alpha-DC1 Vaccines
Phase of Trial: Phase I/II
Latest Information Update: 28 Sep 2017
At a glance
- Drugs Dendritic cell vaccine-Bioclones (Primary) ; Rintatolimod (Primary) ; Celecoxib; Cisplatin; Interferon alpha-2b
- Indications Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions; Therapeutic Use
- 25 Sep 2017 Planned primary completion date changed from 1 Jul 2017 to 31 Jul 2018.
- 10 Jun 2017 Biomarkers information updated
- 26 Dec 2015 According to ClinicalTrials.gov record, status changed from not yet recruiting to recruiting.